相关临床试验
744
104 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
80
10.8%
已完成
427
57.4%
Enrolling By Invitation
8
1.1%
尚未招募
16
2.1%
招募中
142
19.1%
终止
37
5.0%
Unknown
1
0.1%
撤回
33
4.4%
暂无批准数据
- A first-of-its-kind meta-analysis of 574 men with oligometastatic prostate cancer demonstrates that metastasis-directed therapy significantly improves progression-free survival by 7.6 months compared to standard care alone. - The WOLVERINE study, published in The Lancet Oncology, provides the highest level of evidence to date supporting metastasis-directed therapy, primarily stereotactic body radiation therapy, for treating limited metastatic disease. - Patients receiving metastasis-directed therapy showed consistent benefits across multiple endpoints including radiographic progression-free survival and castration resistance-free survival, with no additional safety risks observed.
- Virometix AG has successfully completed enrollment of 60 healthy subjects aged 18-45 years in its Phase I clinical trial of V-212, a fully synthetic, serotype-independent vaccine candidate targeting Streptococcus pneumoniae infections. - The V-212 vaccine utilizes a proprietary Synthetic Virus-Like Particle (SVLP) platform with conformational synthetic peptide mimetics designed to provide broad immunity across diverse pneumococcal serotypes, addressing limitations of current conjugate vaccines. - Preclinical studies demonstrated that V-212 prevented lethal sepsis in serotype 3 challenge models, inhibited bacterial dissemination into blood, and provided protection against serotype 8 infections in mouse and rabbit models. - The randomized, double-blind, placebo-controlled trial is being conducted in collaboration with CEVAC at Ghent University Hospital, with topline safety and immunogenicity data expected in Q1 2026.
- Osivax announced completion of patient visits in its Phase 2a booster trial evaluating OVX836, a broad-spectrum influenza A vaccine candidate targeting the highly conserved nucleoprotein antigen. - The randomized, double-blind trial enrolled 117 healthy adults aged 20-64 who previously participated in Phase 2 trials conducted 3-5 years ago, testing booster doses at 180μg or 480μg. - OVX836 represents a first-in-class approach using oligoDOM™ nanoparticle technology to target the nucleoprotein, which is less likely to mutate than surface antigens. - Final results are expected in the second half of 2025, with the trial uniquely assessing immune response persistence and boostability over an extended timeframe.
